Aura Biosciences (AURA) Accumulated Expenses (2020 - 2026)
Aura Biosciences' (AURA) quarterly Accumulated Expenses came in at $10.9 million in Q1 2026, up 293.27% YoY from $2.8 million in Q1 2025, and down 20.05% on a QoQ basis from $13.6 million in Q4 2025.
Aura Biosciences (AURA) Accumulated Expenses (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Accumulated Expenses data on file, last reported at $10.9 million in Q1 2026.
- Quarterly Accumulated Expenses rose 293.27% year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (up 293.27% YoY) and the FY2025 annual result came in at $13.6 million, up 149.1% from the prior year.
- Accumulated Expenses slipped to $10.9 million in Q1 2026, from $13.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $13.6 million in Q4 2025 to a low of $2.4 million in Q1 2022.
- A 5-year average of $5.7 million and a median of $5.0 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses slumped 44.83% — and 2026, when it jumped 293.27%.
- Tracing AURA's Accumulated Expenses over 5 years: stood at $4.6 million in 2022, then dropped by 23.4% to $3.5 million in 2023, then soared by 55.75% to $5.5 million in 2024, then soared by 149.1% to $13.6 million in 2025, then declined by 20.05% to $10.9 million in 2026.
- The last three Accumulated Expenses figures came in at $10.9 million (Q1 2026), $13.6 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.01 Mn |
| Mar 31, 2026 | 10.87 Mn |
| Dec 31, 2025 | 13.59 Mn |
| Sep 30, 2025 | 6.10 Mn |
| Jun 30, 2025 | 4.39 Mn |
| Mar 31, 2025 | 2.76 Mn |
| Dec 31, 2024 | 5.46 Mn |
| Sep 30, 2024 | 9.60 Mn |
| Jun 30, 2024 | 6.34 Mn |
| Mar 31, 2024 | 4.99 Mn |
| Dec 31, 2023 | 3.50 Mn |
| Sep 30, 2023 | 2.92 Mn |
| Jun 30, 2023 | 5.33 Mn |
| Mar 31, 2023 | 4.07 Mn |
| Dec 31, 2022 | 4.57 Mn |
| Sep 30, 2022 | 5.30 Mn |
| Jun 30, 2022 | 3.98 Mn |
| Mar 31, 2022 | 2.42 Mn |
| Dec 31, 2021 | 4.34 Mn |
| Sep 30, 2021 | 3.49 Mn |